Pfizer and Lilly's tanezumab largely makes the efficacy cut in second PhIII study, but safety issues continue to blight anti-NGF drug
Stark safety issues in the field of anti-NGF pain drugs have led a number of high profile drugmakers to press pause on development, reduce doses …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
